Literature DB >> 23611040

Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.

J Sellner1, W Koczi, A Harrer, K Oppermann, E Obregon-Castrillo, G Pilz, P Wipfler, S Afazel, E Haschke-Becher, E Trinka, J Kraus.   

Abstract

An altered expression pattern of adhesion molecules (AM) on the surface of immune cells is a premise for their extravasation into the central nervous system (CNS) and the formation of acute brain lesions in multiple sclerosis (MS). We evaluated the impact of glatiramer acetate (GA) on cell-bound and soluble AM in the peripheral blood of patients with relapsing-remitting MS (RRMS). Fifteen patients treated de novo with GA were studied on four occasions over a period of 12 months. Surface levels of intracellular cell adhesion molecule (ICAM)-1, ICAM-3, lymphocyte function-associated antigen (LFA)-1 and very late activation antigen (VLA)-4 were assessed in T cells (CD3(+) CD8(+) , CD3(+) CD4(+) ), B cells, natural killer (NK) cells, natural killer T cells (NK T) and monocytes by five-colour flow cytometry. Soluble E-selectin, ICAM-1, ICAM-3, platelet endothelial cell adhesion molecule (PECAM)-1, P-selectin and vascular cell adhesion molecule (VCAM)-1 were determined with a fluorescent bead-based immunoassay. The pro-migratory pattern in RRMS was verified by comparison with healthy controls and was characterized by up-regulation of LFA-1 (CD3(+) CD4(+) T cells, B cells), VLA-4 (CD3(+) CD8(+) T cells, NK cells), ICAM-1 (B cells) and ICAM-3 (NK cells). Effects of GA treatment were most pronounced after 6 months and included attenuated levels of LFA-1 (CD3(+) CD4(+) ) and VLA-4 (CD3(+) CD4(+) , CD3(+) CD8(+) , NK, NK T, monocytes). Further effects included lowering of ICAM-1 and ICAM-3 levels in almost all immune cell subsets. Soluble AM levels in RRMS did not differ from healthy controls and remained unaltered after GA treatment. The deregulated pro-migratory expression profile of cell-bound AM is altered by GA treatment. While this alteration may contribute to the beneficial action of the drug, the protracted development and unselective changes indicate more secondary immune regulatory phenomena related to these effects.
© 2013 British Society for Immunology.

Entities:  

Keywords:  adhesion molecule; glatiramer-acetate; immunomodulation; multiple sclerosis; transmigration

Mesh:

Substances:

Year:  2013        PMID: 23611040      PMCID: PMC3949625          DOI: 10.1111/cei.12125

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Determinants of human B cell migration across brain endothelial cells.

Authors:  Andrea Alter; Martin Duddy; Sherry Hebert; Katarzyna Biernacki; Alexandre Prat; Jack P Antel; Voon Wee Yong; Robert K Nuttall; Caroline J Pennington; Dylan R Edwards; Amit Bar-Or
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

2.  Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions.

Authors:  L Bö; J W Peterson; S Mørk; P A Hoffman; W M Gallatin; R M Ransohoff; B D Trapp
Journal:  J Neuropathol Exp Neurol       Date:  1996-10       Impact factor: 3.685

3.  Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis.

Authors:  P Rieckmann; B Altenhofen; A Riegel; J Baudewig; K Felgenhauer
Journal:  Ann Neurol       Date:  1997-03       Impact factor: 10.422

4.  CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1.

Authors:  Luca Battistini; Laura Piccio; Barbara Rossi; Simona Bach; Simona Galgani; Claudio Gasperini; Linda Ottoboni; Donatella Ciabini; Maria D Caramia; Giorgio Bernardi; Carlo Laudanna; Elio Scarpini; Rodger P McEver; Eugene C Butcher; Giovanna Borsellino; Gabriela Constantin
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

5.  Migration of multiple sclerosis lymphocytes through brain endothelium.

Authors:  Alexandre Prat; Katarzyna Biernacki; Jean-Francois Lavoie; Josee Poirier; Pierre Duquette; Jack P Antel
Journal:  Arch Neurol       Date:  2002-03

6.  Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.

Authors:  Joerg Kraus; Roland Bauer; Nikolaos Chatzimanolis; Britta Engelhardt; Jasmin Tofighi; Thomas Bregenzer; Benedikte S Kuehne; Erwin Stolz; Franz Blaes; Katrin Morgen; Horst Traupe; Manfred Kaps; Patrick Oschmann
Journal:  J Neurol       Date:  2004-04       Impact factor: 4.849

7.  Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS.

Authors:  Jorge Correale; María de los Milagros Bassani Molinas
Journal:  J Neuroimmunol       Date:  2003-07       Impact factor: 3.478

Review 8.  Multiple sclerosis: immune system molecule expression in the central nervous system.

Authors:  C S Raine
Journal:  J Neuropathol Exp Neurol       Date:  1994-07       Impact factor: 3.685

9.  Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients.

Authors:  Ho Jin Kim; Katarzyna Biernacki; Alexandre Prat; Jack P Antel; Amit Bar-Or
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

10.  Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation.

Authors:  Isabell Hamann; Jan Dörr; Robert Glumm; Coralie Chanvillard; Antonia Janssen; Jason M Millward; Friedemann Paul; Richard M Ransohoff; Carmen Infante-Duarte
Journal:  J Neuroimmunol       Date:  2012-09-02       Impact factor: 3.478

View more
  12 in total

Review 1.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 2.  Immune regulation of multiple sclerosis by CD8+ T cells.

Authors:  Sushmita Sinha; Farah R Itani; Nitin J Karandikar
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 3.  B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Authors:  Silke Kinzel; Martin S Weber
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

4.  High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  A Harrer; G Pilz; P Wipfler; K Oppermann; J Sellner; W Hitzl; E Haschke-Becher; S Afazel; T Rispens; D van der Kleij; E Trinka; J Kraus
Journal:  Clin Exp Immunol       Date:  2015-04-27       Impact factor: 4.330

Review 5.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

6.  Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.

Authors:  Sarah Kolitz; Tal Hasson; Fadi Towfic; Jason M Funt; Shlomo Bakshi; Kevin D Fowler; Daphna Laifenfeld; Augusto Grinspan; Maxim N Artyomov; Tal Birnberg; Rivka Schwartz; Arthur Komlosh; Liat Hayardeny; David Ladkani; Michael R Hayden; Benjamin Zeskind; Iris Grossman
Journal:  Sci Rep       Date:  2015-05-22       Impact factor: 4.379

Review 7.  Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.

Authors:  Klaus Lehmann-Horn; Silke Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2017-09-23       Impact factor: 5.923

Review 8.  B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.

Authors:  Nele Claes; Judith Fraussen; Piet Stinissen; Raymond Hupperts; Veerle Somers
Journal:  Front Immunol       Date:  2015-12-21       Impact factor: 7.561

9.  The contribution of the acute phase response to the pathogenesis of relapse in chronic-relapsing experimental autoimmune encephalitis models of multiple sclerosis.

Authors:  Silvy Mardiguian; Emma Ladds; Roberta Turner; Hazel Shepherd; Sandra J Campbell; Daniel C Anthony
Journal:  J Neuroinflammation       Date:  2017-09-30       Impact factor: 8.322

10.  Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

Authors:  Sunny Malhotra; Luisa M Villar; Carme Costa; Luciana Midaglia; Marta Cubedo; Silvia Medina; Nicolás Fissolo; Jordi Río; Joaquín Castilló; José C Álvarez-Cermeño; Alex Sánchez; Xavier Montalban; Manuel Comabella
Journal:  J Neuroinflammation       Date:  2018-10-26       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.